TransThera Sciences (Nanjing) (HKG:2617) dosed the first patient in a phase II clinical trial of tinengotinib in China, according to a Friday Hong Kong bourse filing.
The trial is testing the safety and efficacy of the drug in combination with novel hormonal therapy for pretreated and progressed metastatic castration-resistant prostate cancer.